NeoGenomics
About: NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
Employees: 2,100
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
449% more call options, than puts
Call options by funds: $12.3M | Put options by funds: $2.24M
48% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 25
3% more funds holding
Funds holding: 258 [Q2] → 267 (+9) [Q3]
2% more capital invested
Capital invested by funds: $1.78B [Q2] → $1.82B (+$40.7M) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
4.05% less ownership
Funds ownership: 100.74% [Q2] → 96.69% (-4.05%) [Q3]
23% less repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 93
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Needham Mike Matson 52% 1-year accuracy 64 / 122 met price target | 34%upside $19 | Buy Reiterated | 15 Jan 2025 |
B of A Securities Derik De Bruin 68% 1-year accuracy 13 / 19 met price target | 34%upside $19 | Neutral Maintained | 13 Dec 2024 |
Jefferies Tycho Peterson 42% 1-year accuracy 5 / 12 met price target | 55%upside $22 | Buy Initiated | 10 Dec 2024 |
Financial journalist opinion
Based on 6 articles about NEO published over the past 30 days
